All In Biotech

Drug Trial Radar · NCT00426764

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)

Last checked: Nov 20, 2026Latest source record: Feb 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

131

Actual

Start

Jun 19, 2007

Primary completion

Nov 11, 2010

Study completion May 17, 2018

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

  • RomidepsinDrug

    Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an Independent Review CommitteeTime frame: Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.

Locations

90 sites in 10 countries. Site status is shown where the registry gives one.

  • Moore UCSD Cancer Center

    La Jolla, California

  • UCLA Division of Hematology Oncology

    Los Angeles, California

  • University of California, San Francisco

    San Francisco, California

  • Rocky Mountain Cancer Centers-Aurora

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Georgetown University IRB

    Washington D.C., District of Columbia

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • Cancer Centers of Florida, PA

    Orlando, Florida

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Augusta Oncology Associates, P.C.

    Augusta, Georgia

  • Central Georgia Cancer Care

    Macon, Georgia

  • Cancer Care and Hematology Specialists of Chicagoland

    Arlington Heights, Illinois

  • Hematology Oncology Assoc. of IL Orchard Research LLC

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Consultants in Blood Disorders and Cancer

    Louisville, Kentucky

  • St. Agnes - Medical Center

    Baltimore, Maryland

  • Center for Cancer And Blood Disorders

    Bethesda, Maryland

  • Center for Cancer Research CAMC

    Bethesda, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Minnesota Oncology Hematology, PA

    Burnsville, Minnesota

  • St. Joseph Oncology, Inc

    Saint Joseph, Missouri

  • Arch Medical Services

    St Louis, Missouri

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Taussig Cancer Center Cleveland Clinic Foundation

    Cleveland, Ohio

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon

  • Accelerated Community Oncology Research Network Inc ACORN

    Memphis, Tennessee

  • Mamie McFadden Ward Center

    Beaumont, Texas

  • Methodist Charlton Cancer Center

    Dallas, Texas

  • UT Southwestern Medical Center Simmons Comprehensive Cancer Center

    Dallas, Texas

  • El Paso Cancer Treatment Center

    El Paso, Texas

  • Texas Oncology, P.A.-Fort Worth

    Fort Worth, Texas

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Allison Cancer Center

    Midland, Texas

  • US Oncology

    Plano, Texas

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.